Details of the Drug

General Information of Drug (ID: DML5VQ0)

Drug Name
Fenoprofen
Synonyms
Fenoprofene; Fenoprofeno; Fenoprofenum; Feprona; Nalfon; Nalgesic; Feneprofen calcium salt dihydrate; Fenoprofen calcium; Fenoprofen calcium hydrate; Lilly 53838; Fenoprofen Dihydrate, Calcium Salt; Fenoprofene [INN-French]; Fenoprofeno [INN-Spanish]; Fenoprofenum [INN-Latin]; Fenopron (TN); Fenoprofen (USAN/INN); Fenoprofen [USAN:BAN:INN]; Alpha-(m-phenoxyphenyl)propionic acid; Alpha-Methyl-3-phenoxybenzeneacetic acid; (+-)-2-(3-Phenoxyphenyl)propionic acid; (+-)-m-Phenoxyhydratropic acid; 2-(3-Phenoxyphenyl)propanoic acid; 2-(3-Phenoxyphenyl)propionic acid; 2-(m-phenoxyphenyl)propionic acid; 2-[3-(phenyloxy)phenyl]propanoic acid
Indication
Disease Entry ICD 11 Status REF
Rheumatoid arthritis FA20 Approved [1], [2]
Therapeutic Class
Antiinflammatory Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 242.27
Topological Polar Surface Area (xlogp) 3.3
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.6 mL/min/kg [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 3 hours [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 206.37532 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.02% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.1 L/kg [4]
Chemical Identifiers
Formula
C15H14O3
IUPAC Name
2-(3-phenoxyphenyl)propanoic acid
Canonical SMILES
CC(C1=CC(=CC=C1)OC2=CC=CC=C2)C(=O)O
InChI
InChI=1S/C15H14O3/c1-11(15(16)17)12-6-5-9-14(10-12)18-13-7-3-2-4-8-13/h2-11H,1H3,(H,16,17)
InChIKey
RDJGLLICXDHJDY-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3342
ChEBI ID
CHEBI:5004
CAS Number
29679-58-1
DrugBank ID
DB00573
TTD ID
D03XYW
ACDINA ID
D00270

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin G/H synthase (COX) TTK0943 PGH1_HUMAN; PGH2_HUMAN Inhibitor [6], [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Fenoprofen
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Sulfasalazine DMICA9H Moderate Increased risk of nephrotoxicity by the combination of Fenoprofen and Sulfasalazine. Rheumatoid arthritis [FA20] [17]
Dexamethasone DMMWZET Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Fenoprofen and Dexamethasone. Rheumatoid arthritis [FA20] [18]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Fenoprofen and Leflunomide. Rheumatoid arthritis [FA20] [19]
Coadministration of a Drug Treating the Disease Different from Fenoprofen (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Fenoprofen and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [20]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Fenoprofen and Repaglinide. Acute diabete complication [5A2Y] [21]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Fenoprofen and Glibenclamide. Acute diabete complication [5A2Y] [21]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Fenoprofen and Tolazamide. Acute diabete complication [5A2Y] [21]
Nateglinide DMLK2QH Moderate Increased risk of hypoglycemia by the combination of Fenoprofen and Nateglinide. Acute diabete complication [5A2Y] [21]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Fenoprofen and Glipizide. Acute diabete complication [5A2Y] [21]
Inotersen DMJ93CT Major Increased risk of bleeding by the combination of Fenoprofen and Inotersen. Amyloidosis [5D00] [22]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Fenoprofen and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [23]
Methylphenobarbital DMDSWAG Minor Increased metabolism of Fenoprofen caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [24]
Cilostazol DMZMSCT Moderate Increased risk of bleeding by the combination of Fenoprofen and Cilostazol. Arterial occlusive disease [BD40] [25]
Budesonide DMJIBAW Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Fenoprofen and Budesonide. Asthma [CA23] [18]
Ofloxacin DM0VQN3 Moderate Additive CNS depression effects by the combination of Fenoprofen and Ofloxacin. Bacterial infection [1A00-1C4Z] [26]
Kanamycin DM2DMPO Moderate Increased risk of nephrotoxicity by the combination of Fenoprofen and Kanamycin. Bacterial infection [1A00-1C4Z] [27]
Trovafloxacin DM6AN32 Moderate Additive CNS depression effects by the combination of Fenoprofen and Trovafloxacin. Bacterial infection [1A00-1C4Z] [26]
Sparfloxacin DMB4HCT Moderate Additive CNS depression effects by the combination of Fenoprofen and Sparfloxacin. Bacterial infection [1A00-1C4Z] [26]
Streptomycin DME1LQN Moderate Increased risk of nephrotoxicity by the combination of Fenoprofen and Streptomycin. Bacterial infection [1A00-1C4Z] [27]
Gemifloxacin DMHT34O Moderate Additive CNS depression effects by the combination of Fenoprofen and Gemifloxacin. Bacterial infection [1A00-1C4Z] [26]
Norfloxacin DMIZ6W2 Moderate Additive CNS depression effects by the combination of Fenoprofen and Norfloxacin. Bacterial infection [1A00-1C4Z] [26]
ABT-492 DMJFD2I Moderate Additive CNS depression effects by the combination of Fenoprofen and ABT-492. Bacterial infection [1A00-1C4Z] [26]
Gentamicin DMKINJO Moderate Increased risk of nephrotoxicity by the combination of Fenoprofen and Gentamicin. Bacterial infection [1A00-1C4Z] [27]
Netilmicin DMRD1QK Moderate Increased risk of nephrotoxicity by the combination of Fenoprofen and Netilmicin. Bacterial infection [1A00-1C4Z] [27]
Levofloxacin DMS60RB Moderate Additive CNS depression effects by the combination of Fenoprofen and Levofloxacin. Bacterial infection [1A00-1C4Z] [26]
Tobramycin DMUI0CH Moderate Increased risk of nephrotoxicity by the combination of Fenoprofen and Tobramycin. Bacterial infection [1A00-1C4Z] [27]
Lomefloxacin DMVRH9C Moderate Additive CNS depression effects by the combination of Fenoprofen and Lomefloxacin. Bacterial infection [1A00-1C4Z] [26]
Etidronic acid DM1XHYJ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Fenoprofen and Etidronic acid. Bone paget disease [FB85] [28]
Risedronate DM5FLTY Moderate Increased risk of nephrotoxicity by the combination of Fenoprofen and Risedronate. Bone paget disease [FB85] [28]
Alendronate DMY2KX9 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Fenoprofen and Alendronate. Bone paget disease [FB85] [28]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Fenoprofen and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [29]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Fenoprofen and Iodipamide. Cholelithiasis [DC11] [30]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Fenoprofen and Levomilnacipran. Chronic pain [MG30] [31]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Fenoprofen and Regorafenib. Colorectal cancer [2B91] [22]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Fenoprofen and Drospirenone. Contraceptive management [QA21] [32]
Thiopental DMGP8AX Minor Increased metabolism of Fenoprofen caused by Thiopental mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [24]
Methoxyflurane DML0RAE Moderate Increased risk of nephrotoxicity by the combination of Fenoprofen and Methoxyflurane. Corneal disease [9A76-9A78] [22]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Fenoprofen and Ardeparin. Coronary thrombosis [BA43] [33]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Fenoprofen and Danaparoid. Deep vein thrombosis [BD71] [33]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Fenoprofen and Rivaroxaban. Deep vein thrombosis [BD71] [34]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Fenoprofen and Vilazodone. Depression [6A70-6A7Z] [31]
Paroxetine DM5PVQE Moderate Increased risk of bleeding by the combination of Fenoprofen and Paroxetine. Depression [6A70-6A7Z] [31]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Fenoprofen and Vortioxetine. Depression [6A70-6A7Z] [31]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Fenoprofen and Milnacipran. Depression [6A70-6A7Z] [31]
Escitalopram DMFK9HG Moderate Increased risk of bleeding by the combination of Fenoprofen and Escitalopram. Depression [6A70-6A7Z] [31]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Fenoprofen and Desvenlafaxine. Depression [6A70-6A7Z] [31]
Clomipramine DMINRKW Moderate Increased risk of bleeding by the combination of Fenoprofen and Clomipramine. Depression [6A70-6A7Z] [31]
PMID28870136-Compound-49 DMTUC9E Moderate Increased risk of bleeding by the combination of Fenoprofen and PMID28870136-Compound-49. Discovery agent [N.A.] [35]
Fenfluramine DM0762O Moderate Increased risk of bleeding by the combination of Fenoprofen and Fenfluramine. Epilepsy/seizure [8A61-8A6Z] [31]
Primidone DM0WX6I Minor Increased metabolism of Fenoprofen caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [24]
Phenobarbital DMXZOCG Minor Increased metabolism of Fenoprofen caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [24]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Fenoprofen and Cannabidiol. Epileptic encephalopathy [8A62] [22]
Ethacrynic acid DM60QMR Moderate Antagonize the effect of Fenoprofen when combined with Ethacrynic acid. Essential hypertension [BA00] [36]
Tazemetostat DMWP1BH Moderate Increased risk of bleeding by the combination of Fenoprofen and Tazemetostat. Follicular lymphoma [2A80] [25]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Fenoprofen and Avapritinib. Gastrointestinal stromal tumour [2B5B] [22]
Sulfinpyrazone DMEV954 Moderate Increased risk of bleeding by the combination of Fenoprofen and Sulfinpyrazone. Gout [FA25] [25]
Eplerenone DMF0NQR Moderate Antagonize the effect of Fenoprofen when combined with Eplerenone. Heart failure [BD10-BD1Z] [37]
Chlorothiazide DMLHESP Moderate Antagonize the effect of Fenoprofen when combined with Chlorothiazide. Heart failure [BD10-BD1Z] [36]
Furosemide DMMQ8ZG Moderate Antagonize the effect of Fenoprofen when combined with Furosemide. Heart failure [BD10-BD1Z] [36]
Amiloride DMRTSGP Moderate Antagonize the effect of Fenoprofen when combined with Amiloride. Heart failure [BD10-BD1Z] [36]
Hydroflumethiazide DMVPUQI Moderate Antagonize the effect of Fenoprofen when combined with Hydroflumethiazide. Heart failure [BD10-BD1Z] [36]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Fenoprofen and Brentuximab vedotin. Hodgkin lymphoma [2B30] [38]
Efavirenz DMC0GSJ Moderate Increased risk of hepatotoxicity by the combination of Fenoprofen and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [39]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Fenoprofen and Mipomersen. Hyper-lipoproteinaemia [5C80] [40]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Fenoprofen and Teriflunomide. Hyper-lipoproteinaemia [5C80] [19]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Fenoprofen and BMS-201038. Hyper-lipoproteinaemia [5C80] [41]
Indapamide DMGN1PW Moderate Antagonize the effect of Fenoprofen when combined with Indapamide. Hypertension [BA00-BA04] [36]
Trichlormethiazide DMHAQCO Moderate Antagonize the effect of Fenoprofen when combined with Trichlormethiazide. Hypertension [BA00-BA04] [36]
Hydrochlorothiazide DMUSZHD Moderate Antagonize the effect of Fenoprofen when combined with Hydrochlorothiazide. Hypertension [BA00-BA04] [36]
Dipyridamole DMXY30O Moderate Increased risk of bleeding by the combination of Fenoprofen and Dipyridamole. Hypertension [BA00-BA04] [25]
Potassium chloride DMMTAJC Moderate Increased risk of hyperkalemia by the combination of Fenoprofen and Potassium chloride. Hypo-kalaemia [5C77] [42]
Balsalazide DMO091F Moderate Increased risk of nephrotoxicity by the combination of Fenoprofen and Balsalazide. Indeterminate colitis [DD72] [17]
Amobarbital DM0GQ8N Minor Increased metabolism of Fenoprofen caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [24]
Ibandronate DM0QZBN Moderate Increased risk of nephrotoxicity by the combination of Fenoprofen and Ibandronate. Low bone mass disorder [FB83] [22]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Fenoprofen and Porfimer Sodium. Lung cancer [2C25] [43]
Calaspargase pegol DMQZBXI Moderate Increased risk of bleeding by the combination of Fenoprofen and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [44]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Fenoprofen and Idelalisib. Mature B-cell leukaemia [2A82] [45]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Fenoprofen and Acalabrutinib. Mature B-cell lymphoma [2A85] [46]
Clofarabine DMCVJ86 Moderate Increased risk of nephrotoxicity by the combination of Fenoprofen and Clofarabine. Mature B-cell lymphoma [2A85] [22]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Fenoprofen and Ibrutinib. Mature B-cell lymphoma [2A85] [47]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Fenoprofen and Ponatinib. Mature B-cell lymphoma [2A85] [48]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Fenoprofen and Exjade. Mineral absorption/transport disorder [5C64] [49]
Panobinostat DM58WKG Major Increased risk of bleeding by the combination of Fenoprofen and Panobinostat. Multiple myeloma [2A83] [20]
Deflazacort DMV0RNS Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Fenoprofen and Deflazacort. Muscular dystrophy [8C70] [18]
Ruxolitinib DM7Q98D Moderate Increased risk of bleeding by the combination of Fenoprofen and Ruxolitinib. Myeloproliferative neoplasm [2A20] [25]
Dasatinib DMJV2EK Major Increased risk of bleeding by the combination of Fenoprofen and Dasatinib. Myeloproliferative neoplasm [2A20] [50]
Omacetaxine mepesuccinate DMPU2WX Major Increased risk of bleeding by the combination of Fenoprofen and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [51]
Prasugrel DM7MT6E Major Increased risk of bleeding by the combination of Fenoprofen and Prasugrel. Myocardial infarction [BA41-BA43] [22]
Vorapaxar DMA16BR Major Increased risk of bleeding by the combination of Fenoprofen and Vorapaxar. Myocardial infarction [BA41-BA43] [52]
Tirofiban DMQG17S Moderate Increased risk of bleeding by the combination of Fenoprofen and Tirofiban. Myocardial infarction [BA41-BA43] [53]
Sibutramine DMFJTDI Moderate Increased risk of bleeding by the combination of Fenoprofen and Sibutramine. Obesity [5B80-5B81] [31]
Dexfenfluramine DMJ7YDS Moderate Increased risk of bleeding by the combination of Fenoprofen and Dexfenfluramine. Obesity [5B80-5B81] [31]
Polythiazide DMCH80F Moderate Antagonize the effect of Fenoprofen when combined with Polythiazide. Oedema [MG29] [36]
Diclofenac DMPIHLS Moderate Increased risk of hepatotoxicity by the combination of Fenoprofen and Diclofenac. Osteoarthritis [FA00-FA05] [54]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Fenoprofen and MK-4827. Ovarian cancer [2C73] [22]
Aspirin DM672AH Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Fenoprofen and Aspirin. Pain [MG30-MG3Z] [55]
Prednisone DM2HG4X Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Fenoprofen and Prednisone. Postoperative inflammation [1A00-CA43] [18]
Hydrocortisone DMGEMB7 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Fenoprofen and Hydrocortisone. Postoperative inflammation [1A00-CA43] [18]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Fenoprofen and Epoprostenol. Pulmonary hypertension [BB01] [56]
Iloprost DMVPZBE Moderate Increased risk of bleeding by the combination of Fenoprofen and Iloprost. Pulmonary hypertension [BB01] [56]
Everolimus DM8X2EH Major Increased risk of nephrotoxicity by the combination of Fenoprofen and Everolimus. Renal cell carcinoma [2C90] [57]
Temsirolimus DMS104F Major Increased risk of nephrotoxicity by the combination of Fenoprofen and Temsirolimus. Renal cell carcinoma [2C90] [57]
Gatifloxacin DMSL679 Moderate Additive CNS depression effects by the combination of Fenoprofen and Gatifloxacin. Respiratory infection [CA07-CA4Z] [26]
Methylprednisolone DM4BDON Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Fenoprofen and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [18]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Fenoprofen and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [22]
Prednisolone DMQ8FR2 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Fenoprofen and Prednisolone. Solid tumour/cancer [2A00-2F9Z] [18]
Pitolisant DM8RFNJ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Fenoprofen and Pitolisant. Somnolence [MG42] [22]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Fenoprofen and Naltrexone. Substance abuse [6C40] [58]
Caplacizumab DMPUKA7 Moderate Increased risk of bleeding by the combination of Fenoprofen and Caplacizumab. Thrombocytopenia [3B64] [25]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Fenoprofen and Apixaban. Thrombosis [DB61-GB90] [22]
Cangrelor DM8JRH0 Moderate Increased risk of bleeding by the combination of Fenoprofen and Cangrelor. Thrombosis [DB61-GB90] [25]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Fenoprofen and Brilinta. Thrombosis [DB61-GB90] [22]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Fenoprofen and Cabozantinib. Thyroid cancer [2D10] [59]
Sirolimus DMGW1ID Major Increased risk of nephrotoxicity by the combination of Fenoprofen and Sirolimus. Transplant rejection [NE84] [57]
Tacrolimus DMZ7XNQ Major Increased risk of nephrotoxicity by the combination of Fenoprofen and Tacrolimus. Transplant rejection [NE84] [57]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Fenoprofen and Tolbutamide. Type 2 diabetes mellitus [5A11] [21]
Chlorpropamide DMPHZQE Moderate Increased risk of hypoglycemia by the combination of Fenoprofen and Chlorpropamide. Type 2 diabetes mellitus [5A11] [21]
Olsalazine DMZW9HA Moderate Increased risk of nephrotoxicity by the combination of Fenoprofen and Olsalazine. Ulcerative colitis [DD71] [17]
Cinoxacin DM4EWNS Moderate Additive CNS depression effects by the combination of Fenoprofen and Cinoxacin. Urinary tract infection [GC08] [26]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Fenoprofen and Plazomicin. Urinary tract infection [GC08] [27]
Nalidixic acid DMRM0JV Moderate Additive CNS depression effects by the combination of Fenoprofen and Nalidixic acid. Urinary tract infection [GC08] [26]
Triamcinolone DM98IXF Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Fenoprofen and Triamcinolone. Vasomotor/allergic rhinitis [CA08] [18]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Fenoprofen and Betrixaban. Venous thromboembolism [BD72] [60]
⏷ Show the Full List of 120 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
FD&C blue no. 1 E00263 19700 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Gelatin E00630 Not Available Other agent
Magnesium stearate E00208 11177 lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Colcothar yellow E00436 518696 Colorant
Haematite red E00236 14833 Colorant
⏷ Show the Full List of 18 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Fenoprofen 600 mg tablet 600 mg Oral Tablet Oral
Fenoprofen 400 mg capsule 400 mg Oral Capsule Oral
Fenoprofen 200 mg capsule 200 mg Oral Capsule Oral
Fenoprofen Calcium eq 400mg base capsule eq 400mg base Capsule Oral
Fenoprofen Calcium eq 200mg base capsule eq 200mg base Capsule Oral
Fenoprofen Calcium eq 300mg base capsule eq 300mg base Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4820).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 072267.
3 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007 Apr 1;67(7):3254-62.
7 Immunomodulatory effect of nonsteroidal anti-inflammatory drugs (NSAIDs) at the clinically available doses. Arch Pharm Res. 2007 Jan;30(1):64-74.
8 Mechanism of action of paracetamol. Am J Ther. 2005 Jan-Feb;12(1):46-55.
9 Diclofenac and NS-398, a selective cyclooxygenase-2 inhibitor, decrease agonist-induced contractions of the pig isolated ureter. Urol Res. 2000 Dec;28(6):376-82.
10 Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis. Cardiovasc Hematol Disord Drug Targets. 2008 Dec;8(4):268-77.
11 Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip. Int J Clin Pharmacol Ther. 2003 Apr;41(4):153-64.
12 Cyclooxygenase and nitric oxide synthase dependence of cutaneous reactive hyperemia in humans. Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H425-32.
13 Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann N Y Acad Sci. 1994 Nov 15;744:50-7.
14 Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther. 2003 Sep;74(3):222-35.
15 The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79.
16 Modulation of arachidonic acid metabolism by orally administered morniflumate in man. Agents Actions. 1991 Jul;33(3-4):233-9.
17 Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
18 Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
19 EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
20 Cerner Multum, Inc. "Australian Product Information.".
21 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
22 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
23 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
24 Helleberg L, Rubin A, Wolen RL, et al "A pharmacokinetic interaction in man between phenobarbitone and fenoprofen, a new anti-inflammatory agent." Br J Clin Pharmacol 1 (1974): 371-4. [PMID: 22454912]
25 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
26 Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
27 Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
28 Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
29 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
30 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
31 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
32 Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
33 Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
34 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
35 Canadian Pharmacists Association.
36 Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
37 Abdel-Haq B, Magagna A, Favilla S, Salvetti A "Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects." J Cardiovasc Pharmacol 18 (1991): s33-6. [PMID: 1725198]
38 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
39 Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
40 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
41 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
42 Product Information. Potassium Chloride ER (potassium chloride). Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.
43 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
44 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
45 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
46 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
47 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
48 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
49 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
50 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
51 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
52 Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
53 Product Information. Integrilin (eptifibatide). Schering Laboratories, Kenilworth, NJ.
54 Product Information. Solaraze (diclofenac topical). Doak Dermatologics Division, Fairfield, NJ.
55 Abdel-Rahman MS, Reddi AS, Curro FA, Turkall RM, Kadry AM, Hansrote JA "Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers." Can J Physiol Pharmacol 69 (1991): 1436-42. [PMID: 1777842]
56 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
57 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
58 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
59 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
60 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.